Annovis Bio, Inc.
NYSE · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Annovis Bio is a clinical-stage pharmaceutical company developing drug candidates to treat neurodegenerative diseases, including Alzheimer's and Parkinson's disease, by targeting toxic protein buildup that impairs nerve cell communication. Its lead candidate, buntanetap, is designed to inhibit the production of multiple neurotoxic proteins simultaneously rather than targeting a single pathway.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Hoffman Michael BDirector | Buy | $5.00M | 5,000,000at $1.00 | Nov 6, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable ANVS activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.